NCT05400876

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Relapsed or Refractory Lymphoma

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 92 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a two-phase, open-label Phase Ib clinical trial to evaluate the safety and efficacy of TQB2618 injection combined with Penpulimab in patients with relapsed and refractory lymphoma

Conditions

• Relapsed/Refractory Lymphoma

Interventions

Type	Name	Description
DRUG	TQB2618 injection	TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)
DRUG	Penpulimab injection	Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)

Timeline

• Start date: 2022-06-09
• Primary completion: 2023-05-01
• Completion: 2023-10-01
• First posted: 2022-06-02
• Last updated: 2023-02-14

Locations

1 site across 1 country: China